Sunesis Pharmaceuticals to Present at the 30th Annual Piper Jaffray Healthcare Conference
November 19 2018 - 7:00AM
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that
Willie Quinn, Chief Financial Officer and Senior Vice President,
Finance and Corporate Development of Sunesis, will present at the
30th Annual Piper Jaffray Healthcare Conference on Wednesday,
November 28, 2018 at 7:50 A.M. Eastern Time at the Lotte New York
Palace Hotel in New York City.
A live webcast of the presentation will be
available on the Sunesis website at http://ir.sunesis.com. A
replay will be archived on the "Calendar of Events" page in the
Investors and Media section of the Sunesis website for two
weeks.
About Sunesis
Pharmaceuticals
Sunesis is a biopharmaceutical company
developing new therapeutics for the treatment of hematologic and
solid cancers. Sunesis has built an experienced drug development
organization committed to improving the lives of people with
cancer. The Company is focused on advancing its novel kinase
inhibitor pipeline, with an emphasis on its oral non-covalent BTK
inhibitor vecabrutinib. Vecabrutinib is currently being evaluated
in a Phase 1b/2 study in adults with chronic lymphocytic leukemia
and other B-cell malignancies that have progressed after prior
therapies. The Company’s proprietary PDK1 inhibitor SNS-510 is in
preclinical development. PDK1 is a master kinase that activates
other kinases important to cell growth and survival including
members of the AKT, PKC, RSK, and SGK families. Sunesis plans to
submit an IND for SNS-510 in 2019. Sunesis is exploring strategic
alternatives for vosaroxin, a late-stage investigational product
for relapsed or refractory AML. Sunesis also has an interest in the
pan-RAF inhibitor TAK-580 which is licensed to Takeda. TAK-580 is
in a clinical trial for pediatric low-grade glioma.
For additional information on Sunesis, please
visit www.sunesis.com.
SUNESIS and the logos are trademarks of Sunesis
Pharmaceuticals, Inc.
Investor and Media
Inquiries:Maeve ConneightonArgot Partners212-600-1902 |
Willie QuinnSunesis
Pharmaceuticals Inc.650-266-3716 |
|
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Sep 2023 to Sep 2024